Developing a seizure detection algorithm using heart rate and movement data
Development of a Seizure Detection Algorithm Based on Heart Rate and Movement Analysis
This study is testing a new way to detect seizures in people with drug-resistant epilepsy by using heart rate and movement data to see if it can help predict when seizures might happen.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild Research network |
| Locations | 1 site (Tain-l'Hermitage) |
| Trial ID | NCT05637762 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with drug-resistant epilepsy to develop a seizure detection algorithm that utilizes heart rate and movement analysis. By employing advanced physiological sensors and artificial intelligence, the study aims to monitor seizure frequency and potentially predict seizures. Participants will wear a connected patch that records heart rate and motion, alongside EEG video recordings to gather comprehensive data. The goal is to enhance therapeutic adaptations and reduce the unpredictability of seizures for patients and their caregivers.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with drug-resistant epilepsy who have experienced seizures with notable heart rate variations.
Not a fit: Patients with psychogenic non-epileptic seizures or severe heart conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved seizure management and quality of life for patients with epilepsy.
How similar studies have performed: Other studies have shown promise in using physiological data for seizure detection, making this approach both relevant and innovative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Person over 18 years of age - With drug-resistant epilepsy as defined by the International League Against Epilepsy * Who has at least one recorded seizure with heart rate variation (i.e. tachycardia defined as an increase of 30 bpm or more than 50% over the interictal heart rate and/or bradycardia defined as a heart rate \< 40 bpm or ictal asystole defined as an R-R interval greater than 3 seconds and usually lasting less than 60 seconds) * Informed about the study and signed a consent to participate in the study (and their legal representative for patients under guardianship) * Affiliated or beneficiary of a social insurance plan Exclusion Criteria: * Pregnant or breastfeeding woman * Persons with psychogenic non-epileptic seizures (PNES) * Person with a history of severe heart disease (myocardial infarction, heart failure, rhythm disorder, severe hypertension) * Persons with an implantable cardiac device (pacemaker, implantable defibrillator) * Documented allergy to hydrogel and/or acrylate * Person benefiting from a legal protection measure other than guardianship or curatorship
Where this trial is running
Tain-l'Hermitage
- Institut La Teppe — Tain-l'Hermitage, France (Recruiting)
Study contacts
- Study coordinator: Amelie Yavchitz, MD
- Email: ayavchitz@for.paris
- Phone: +331 48 03 64 54
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.